Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

Nature Communications

Volumn 3, Issue , 2012, Pages

  Shi, Hubing ^a   Moriceau, Gatien ^a   Kong, Xiangju ^a   Lee, Mi Kyung ^a   Lee, Hane ^a   Koya, Richard C ^a,b   Ng, Charles ^a   Chodon, Thinle ^a   Scolyer, Richard A ^c,d   Dahlman, Kimberly B ^e,f   Sosman, Jeffrey A ^e,f   Kefford, Richard F ^c,d   Long, Georgina V ^c,d   Nelson, Stanley F ^a   Ribas, Antoni ^a,b   Lo, Roger S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Vanderbilt Ingram Cancer Center ^*  (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; SELUMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CLINICAL ARTICLE; COPY NUMBER VARIATION; DOWN REGULATION; DRUG SENSITIVITY; EXOME; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; MELANOMA CELL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; CELL LINE; CELL STRAIN HEK293; DNA SEQUENCE; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BENZIMIDAZOLES; CELL LINE; CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, NEOPLASM; EXOME; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE AMPLIFICATION; HEK293 CELLS; HUMANS; INDOLES; MALE; MAP KINASE KINASE 1; MELANOMA; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS, DNA; SULFONAMIDES;

EID: 84859183431     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1727     Document Type: Article

References (20)

1. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002). (Pubitemid 34716871)
2. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
3. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
4. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
5. Kefford, R. et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J. Clin. Oncol. 28(Suppl) abstr. 8503 (2010).
6. Ribas, A. et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J. Clin. Oncol. 29(Suppl) abstr. 8509 (2011).
7. Shi, H., Kong, X., Ribas, A. & Lo, R. S. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to B-RAF(V600E) inhibition. Cancer Res. 71, 5067-5074 (2011).
8. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695 (2010).
9. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
10. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
11. Poulikakos, P. I. et al. Acquired resistance to RAF inhibitors is mediated by splicing isoforms of BRAF (V600E) that dimerize in a RAS independent manner. Nature 480, 387-390 (2011).
12. Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096 (2011).
13. Dumaz, N. et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66, 9483-9491 (2006). (Pubitemid 44623646)
14. Infante, J. R. et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J. Clin. Oncol. 29 (Suppl) abstr. CRA8503 (2011).
15. Sathirapongsasuti, J. F. et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 27, 2648-2654 (2011).
16. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
17. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
18. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
19. Olshen, A. B., Venkatraman, E. S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004). (Pubitemid 41180205)
20. Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639-1645 (2009).